Qualigen Therapeutics Inc

+0.03 (+3.05%)
4:42:40 PM EDT: $0.98 -0.03 (-2.90%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.26M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.5 Million
Adjusted EPS-$0.92
See more estimates
10-Day MA$1.01
50-Day MA$1.05
200-Day MA$1.08
See more pivots

Qualigen Therapeutics Inc Stock, NASDAQ:QLGN

2042 Corte Del Nogal, Suite 3000, Carlsbad, California 92011
United States of America
Phone: +1.760.918.9165
Number of Employees: 38


Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.